A discrete choice experiment to understand preferences of patients with type 2 diabetes treated with injectable non-insulinic agents

Curr Med Res Opin. 2021 Jan;37(1):37-43. doi: 10.1080/03007995.2020.1859468. Epub 2020 Dec 18.

Abstract

Objective: To identify and evaluate the Spanish diabetes mellitus type 2 patients' preferences on injection and medication frequency and complexity of the treatment of diabetes. Additionally, patients' willingness to pay is evaluated.

Methods: A total of 180 patients recruited from five health care centres in Spain completed a discrete choice experiment survey designed to evaluate patients' preferences over three attributes discriminating by age, sex and patients experience with previous treatment. The resulting model was analysed using a conditional (fixed-effects) logistic regression.

Results: Naïve and non-naïve patients were willing to pay 83.25€ for a 'no preparation required' dose. In addition, both groups of patients were willing to pay 44.30€ for a 'simple preparation' dose. In terms of treatment frequency, no-naïve patients preferred a daily injection with freedom of timing before a daily scheduled injection, willing to pay 22.20€. In addition, no-naïve patients were willing to pay 34.61€ for a weekly injection. Finally, the most valued treatment change in naïve patients was to exchange a daily scheduled injection for a weekly injection, willing to pay 14.35€ for that change.

Conclusions: This study shows that patients highly value the avoidance of injections, with weekly dosing clearly preferred over daily dosing. Of the other attributes, a 'no preparation required' dose is clearly preferred over a 'simple preparation' dose. These findings may provide a better understanding of what patients prefer and value in their treatment and provide guidance for clinicians making therapeutic decisions regarding T2DM treatments.

Keywords: Discrete choice experiment; Spain; health technology assessment; patient preference; type 2 diabetes; willingness to pay.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Humans
  • Hypoglycemic Agents* / administration & dosage
  • Hypoglycemic Agents* / economics
  • Hypoglycemic Agents* / therapeutic use
  • Injections* / economics
  • Injections* / psychology
  • Patient Preference*

Substances

  • Hypoglycemic Agents